This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Dursun, S. M. Articles by Deakin, J. F. W. Search for Related Content PubMed PubMed Citation Articles by Dursun, S. M. Articles by Deakin, J. F. W. Social Bookmarking                         What's this?

Augmenting antipsychotic treatment with lamotrigine or topiramate in patients with treatment-resistant schizophrenia: a naturalistic caseseries outcome study

Psychopharmacology Research Unit, Departments of Psychiatry and Pharmacology, Dalhousie University, Halifax, Nova Scotia, Canada; Neuroscience and Psychiatry Unit, University of Manchester, Manchester, UK sdursun{at}is.dal.ca

J. F. W. Deakin

Psychopharmacology Research Unit, Departments of Psychiatry and Pharmacology, Dalhousie University, Halifax, Nova Scotia, Canada; Neuroscience and Psychiatry Unit, University of Manchester, Manchester, UK

The glutamate hyperfunction hypothesis of schizophrenia has been proposed largely on the basis of studies in post-mortem brain and the lack of efficacy of glutamate agonists as antipsychotic drugs. Recent reports have also suggested that the addition of lamotrigine, a glutamate excess release inhibitor, can cause a dramatic improvement in clozapine treatment-resistant patients, as well as attenuate the neuropsychiatric effects of ketamine in healthy volunteers. To explore the glutamate hyperfunction hypothesis, patients with schizophrenia who were treatment-resistant to current antipsychotic medications were augmented with either lamotrigine (n = 17) or topiramate (a glutamate kainate/-amino-3-hydroxy-5-methyl-4-isoxazolaproprionate antagonist that potentiates GABA function) (n = 9) for 24 weeks. Patients receiving lamotrigine augmentation of clozapine had a significant decrease in Brief Psychiatric Rating Scale score after 2 weeks of treatment. There was no significant improvement when lamotrigine was added to risperidone, haloperidol, olanzapine or fluphenthixol. There was also no significant improvement observed with topiramate augmentation of clozapine, olanzapine, haloperidol and fluphenthixol. These preliminary data support previous evidence that lamotrigine is an effective augmentation agent for clozapine. Although limited by sample size, the findings also suggest glutamate hyperfunction in schizophrenia may have a presynaptic basis and that atypicals with low dopamine receptor occupancy may have antagonistic actions on glutamate function which confer additional antipsychotic activity.

Key Words: augmentation • glutamate • glutamate hyperfunction • lamotrigine • schizophrenia • topiramate

Journal of Psychopharmacology, Vol. 15, No. 4, 297-301 (2001)
DOI: 10.1177/026988110101500409


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				D. C Goff Review: lamotrigine may be an effective treatment for clozapine resistant schizophrenia Evid. Based Ment. Health, November 1, 2009; 12(4): 111 - 111. [Full Text] [PDF]

				H Afshar, H Roohafza, G Mousavi, S Golchin, N Toghianifar, M Sadeghi, and M Talaei Topiramate add-on treatment in schizophrenia: a randomised, double-blind, placebo-controlled clinical trial J Psychopharmacol, March 1, 2009; 23(2): 157 - 162. [Abstract] [PDF]

				U. Lang, M. Willbring, R. von Golitschek, A. Schmeisser, K. Matschke, and S M. Tugtekin Clozapine-induced myocarditis after long-term treatment: case presentation and clinical perspectives J Psychopharmacol, July 1, 2008; 22(5): 576 - 580. [Abstract] [PDF]

				C. H. Large Do NMDA receptor antagonist models of schizophrenia predict the clinical efficacy of antipsychotic drugs? J Psychopharmacol, May 1, 2007; 21(3): 283 - 301. [Abstract] [PDF]

				C. Haw and J. Stubbs A survey of the off-label use of mood stabilizers in a large psychiatric hospital J Psychopharmacol, July 1, 2005; 19(4): 402 - 407. [Abstract] [PDF]

				K. Tritt, C. Nickel, C. Lahmann, P. K. Leiberich, W. K. Rother, T. H. Loew, and M. K. Nickel Lamotrigine treatment of aggression in female borderline-patients: a randomized, double-blind, placebo-controlled study J Psychopharmacol, May 1, 2005; 19(3): 287 - 291. [Abstract] [PDF]

				A. Kalyoncu, H. Mirsal, O. Pektas, N. Unsalan, D. Tan, and M. Beyazyurek Use of lamotrigine to augment clozapine in patients with resistant schizophrenia and comorbid alcohol dependence: a potent anti-craving effect? J Psychopharmacol, May 1, 2005; 19(3): 301 - 305. [Abstract] [PDF]

				S. D. BIENENTREU and K.-T. H. KRONMULLER Increase in Risperidone Plasma Level With Lamotrigine Am J Psychiatry, April 1, 2005; 162(4): 811 - 812. [Full Text] [PDF]

				R. W. Kerwin and A. Bolonna Management of clozapine-resistant schizophrenia Adv. Psychiatr. Treat., March 1, 2005; 11(2): 101 - 106. [Abstract] [Full Text] [PDF]

				J. W. Wheless and B. F. D. Bourgeois Choosing Antiepileptic Drugs for Developmentally Normal Children With Specific Epilepsy Syndromes and Behavioral Disorders J Child Neurol, August 1, 2004; 19(1_suppl): S39 - S48. [Abstract] [PDF]

				J. W. Wheless and B. F. D. Bourgeois Choosing Antiepileptic Drugs for Developmentally Normal Children With Specific Epilepsy Syndromes and Behavioral Disorders J Child Neurol, January 1, 2004; 19(1_suppl): S39 - S48. [Abstract] [PDF]